Filing Flows › Zimmer Biomet Holdings (ZBH) › Q3 2026 › vs Q2 2026
Zimmer Biomet Holdings (ZBH) Q3 2026 vs Q2 2026 (quarter over quarter)
Zimmer Biomet Holdings's revenue fell $114M (-5%) from $2.2B in Q2 2026 to $2.1B in Q3 2026. The biggest changes: Knees −$61.4M (-7%); Hips −$26.2M (-5%); Technology and Data Bone Cement and Surgical −$18.8M (-9%). Operating margin 14.9% against 15.0% (-0.1 pts).
Zimmer Biomet Holdings, Q3 2026: revenue $2.1B (+3% year over year), operating margin 14.9%, net earnings $193M, operating cash flow $560M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 14.9% | 15.0% | -0.1 pts |
| Net margin | 9.4% | 9.2% | +0.2 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Knees | $768M | $829M | −$61.4M | -7% |
| SET | $578M | $586M | −$7.7M | -1% |
| Hips | $536M | $563M | −$26.2M | -5% |
| Technology and Data Bone Cement and Surgical | $181M | $199M | −$18.8M | -9% |
| Revenue | $2.1B | $2.2B | −$114M | -5% |
| Operating profit | $308M | $326M | −$18.5M | -6% |
| Costs & expenses | $1.8B | $1.9B | −$95.6M | -5% |
| Pre-tax earnings | $230M | $255M | −$25.0M | -10% |
| Other expense, net | $77.5M | $71.0M | $6.5M | +9% |
| Cost of revenue | $594M | $636M | −$41.0M | -6% |
| Research & development | $106M | $105M | $1.1M | +1% |
| SG&A | $855M | $899M | −$44.3M | -5% |
| Other operating costs | $200M | $211M | −$11.4M | -5% |
| Net earnings | $193M | $200M | −$6.7M | -3% |
| Income tax | $37.2M | $55.5M | −$18.3M | -33% |
| Depreciation & amortization | $282M | $271M | $11.2M | +4% |
| Share-based compensation | $24.2M | $24.6M | −$400K | -2% |
| Working capital & other | $60.9M | −$47.2M | $108M | — |
| Operating cash flow | $560M | $448M | $112M | +25% |
Questions
How much did Zimmer Biomet Holdings's revenue grow quarter over quarter in Q3 2026?
Zimmer Biomet Holdings's revenue fell $114M (-5%) from $2.2B in Q2 2026 to $2.1B in Q3 2026.
What drove Zimmer Biomet Holdings's revenue change in Q3 2026?
Knees −$61.4M (-7%); Hips −$26.2M (-5%); Technology and Data Bone Cement and Surgical −$18.8M (-9%).